» Articles » PMID: 30914058

Encircling the Regions of the Pharmacogenomic Landscape That Determine Drug Response

Overview
Journal Genome Med
Publisher Biomed Central
Specialty Genetics
Date 2019 Mar 28
PMID 30914058
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The integration of large-scale drug sensitivity screens and genome-wide experiments is changing the field of pharmacogenomics, revealing molecular determinants of drug response without the need for previous knowledge about drug action. In particular, transcriptional signatures of drug sensitivity may guide drug repositioning, prioritize drug combinations, and point to new therapeutic biomarkers. However, the inherent complexity of transcriptional signatures, with thousands of differentially expressed genes, makes them hard to interpret, thus giving poor mechanistic insights and hampering translation to clinics.

Methods: To simplify drug signatures, we have developed a network-based methodology to identify functionally coherent gene modules. Our strategy starts with the calculation of drug-gene correlations and is followed by a pathway-oriented filtering and a network-diffusion analysis across the interactome.

Results: We apply our approach to 189 drugs tested in 671 cancer cell lines and observe a connection between gene expression levels of the modules and mechanisms of action of the drugs. Further, we characterize multiple aspects of the modules, including their functional categories, tissue-specificity, and prevalence in clinics. Finally, we prove the predictive capability of the modules and demonstrate how they can be used as gene sets in conventional enrichment analyses.

Conclusions: Network biology strategies like module detection are able to digest the outcome of large-scale pharmacogenomic initiatives, thereby contributing to their interpretability and improving the characterization of the drugs screened.

Citing Articles

Learning and actioning general principles of cancer cell drug sensitivity.

Carli F, Di Chiaro P, Morelli M, Arora C, Bisceglia L, De Oliveira Rosa N Nat Commun. 2025; 16(1):1654.

PMID: 39952993 PMC: 11828915. DOI: 10.1038/s41467-025-56827-5.


scRank infers drug-responsive cell types from untreated scRNA-seq data using a target-perturbed gene regulatory network.

Li C, Shao X, Zhang S, Wang Y, Jin K, Yang P Cell Rep Med. 2024; 5(6):101568.

PMID: 38754419 PMC: 11228399. DOI: 10.1016/j.xcrm.2024.101568.


The Transcriptional Landscape of Immune-Response 3'-UTR Alternative Polyadenylation in Melanoma.

Yang X, Wu Y, Chen X, Qiu J, Huang C Int J Mol Sci. 2024; 25(5).

PMID: 38474285 PMC: 10931711. DOI: 10.3390/ijms25053041.


Current trends and future prospects of drug repositioning in gastrointestinal oncology.

Fatemi N, Karimpour M, Bahrami H, Zali M, Chaleshi V, Riccio A Front Pharmacol. 2024; 14:1329244.

PMID: 38239190 PMC: 10794567. DOI: 10.3389/fphar.2023.1329244.


Gene Expression and Drug Sensitivity Analysis of Mitochondrial Chaperones Reveals That HSPD1 and TRAP1 Expression Correlates with Sensitivity to Inhibitors of DNA Replication and Mitosis.

Badarni M, Gabbay S, Elkabets M, Rotblat B Biology (Basel). 2023; 12(7).

PMID: 37508418 PMC: 10376793. DOI: 10.3390/biology12070988.


References
1.
Gelderloos J, Rosenkranz S, Bazenet C, Kazlauskas A . A role for Src in signal relay by the platelet-derived growth factor alpha receptor. J Biol Chem. 1998; 273(10):5908-15. DOI: 10.1074/jbc.273.10.5908. View

2.
Juan-Blanco T, Duran-Frigola M, Aloy P . Rationalizing Drug Response in Cancer Cell Lines. J Mol Biol. 2018; 430(18 Pt A):3016-3027. DOI: 10.1016/j.jmb.2018.03.021. View

3.
Oprea T, Bologa C, Brunak S, Campbell A, Gan G, Gaulton A . Unexplored therapeutic opportunities in the human genome. Nat Rev Drug Discov. 2018; 17(5):317-332. PMC: 6339563. DOI: 10.1038/nrd.2018.14. View

4.
Hartwell L, Hopfield J, Leibler S, Murray A . From molecular to modular cell biology. Nature. 1999; 402(6761 Suppl):C47-52. DOI: 10.1038/35011540. View

5.
Nevins J, Potti A . Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet. 2007; 8(8):601-9. DOI: 10.1038/nrg2137. View